Investigation of Herpes Viridea and Parvovirus B19 Frequencies in Lymphopenic Malignant Patients Receiving Chemotherapy

Adil Furkan Kılıç; Salim Başol Tekin

Makale detayları

Investigation of Herpes Viridea and Parvovirus B19 Frequencies in Lymphopenic Malignant Patients Receiving Chemotherapy

Yazarlar:

Adil Furkan Kılıç | Salim Başol Tekin

Yayıncı:

Van Yuzuncu Yıl University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Van Sağlık Bilimleri Dergisi Vol.17 Issue 3, pp.159-165

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001337201

pISSN:

2667-5072

Anahtar kelimeler:

Özet:

 BackgroundAims: In this study, we aimed to investigate the incidence of Epstein-Barr virus EBV, Herpes simplex virus HSV, Cytomegalovirus CMV and Parvovirus B19 viral infections in patients diagnosed with cancer receiving chemotherapy in our clinic. Methods: In this study, 138 lymphopenic patients who were hospitalized and received chemotherapy at Medical Oncology Clinic between April 2018 and July 2018 were evaluated prospectively. Cancer diagnoses of the patients included in the study were lung, esophagus, prostate, breast, pancreatic, colorectal, stomach, brain and nervous system, ovarian and others ewing sarcoma, hepatocellular carcinoma, larynx carcinoma, bladder carcinoma, malignant mesenchymal tumor, multiple myeloma, primary unknown lymphoma, metastatic carcinoma of unknown primary, renal cell carcinoma, cervical carcinoma, testicular carcinoma cancers. The patients were at various stages of cancer, had various histological subtypes, and were receiving various chemotherapies. The  frequency of EBV, HSV, CMV and Parvovirus B19 in serum samples were determined. Results: The mean age of the patients was 58.93  13.28 years, and the mean duration of diagnosis was 2,0  2,2 years. EBV PCR positivity was detected in 9 patients 6.5, CMV PCR positivity in 12 patients 8.7, and EBV and CMV together PCR positivity in 1 0,7 patient. HSV and parvovirus B19 PCR positivitys were not determined in any patients. According to the results of the survival analysis, the average survival time in all lymphopenic patients was 3.71 months. It was observed that 65.21 of all lymphopenic patients die within 12 months following lymphopenia diagnosis. Conclusions: As a result of our study, EBV and CMV PCR positivity rates were determined in all lymphopenic patients receiving chemotherapy 6.5 and 8.7, respectively. More comprehensive studies are needed to determine the incidence of HSV and parvovirus B19. In addition, lymphopenic patients receiving chemotherapy should be followed up by physicians for viral infections and treated with antiviral therapy in the early stages of infection.

 BackgroundAims: In this study, we aimed to investigate the incidence of Epstein-Barr virus EBV, Herpes simplex virus HSV, Cytomegalovirus CMV and Parvovirus B19 viral infections in patients diagnosed with cancer receiving chemotherapy in our clinic. Methods: In this study, 138 lymphopenic patients who were hospitalized and received chemotherapy at Medical Oncology Clinic between April 2018 and July 2018 were evaluated prospectively. Cancer diagnoses of the patients included in the study were lung, esophagus, prostate, breast, pancreatic, colorectal, stomach, brain and nervous system, ovarian and others ewing sarcoma, hepatocellular carcinoma, larynx carcinoma, bladder carcinoma, malignant mesenchymal tumor, multiple myeloma, primary unknown lymphoma, metastatic carcinoma of unknown primary, renal cell carcinoma, cervical carcinoma, testicular carcinoma cancers. The patients were at various stages of cancer, had various histological subtypes, and were receiving various chemotherapies. The  frequency of EBV, HSV, CMV and Parvovirus B19 in serum samples were determined. Results: The mean age of the patients was 58.93  13.28 years, and the mean duration of diagnosis was 2,0  2,2 years. EBV PCR positivity was detected in 9 patients 6.5, CMV PCR positivity in 12 patients 8.7, and EBV and CMV together PCR positivity in 1 0,7 patient. HSV and parvovirus B19 PCR positivitys were not determined in any patients. According to the results of the survival analysis, the average survival time in all lymphopenic patients was 3.71 months. It was observed that 65.21 of all lymphopenic patients die within 12 months following lymphopenia diagnosis. Conclusions: As a result of our study, EBV and CMV PCR positivity rates were determined in all lymphopenic patients receiving chemotherapy 6.5 and 8.7, respectively. More comprehensive studies are needed to determine the incidence of HSV and parvovirus B19. In addition, lymphopenic patients receiving chemotherapy should be followed up by physicians for viral infections and treated with antiviral therapy in the early stages of infection.

 BackgroundAims: In this study, we aimed to investigate the incidence of Epstein-Barr virus EBV, Herpes simplex virus HSV, Cytomegalovirus CMV and Parvovirus B19 viral infections in patients diagnosed with cancer receiving chemotherapy in our clinic. Methods: In this study, 138 lymphopenic patients who were hospitalized and received chemotherapy at Medical Oncology Clinic between April 2018 and July 2018 were evaluated prospectively. Cancer diagnoses of the patients included in the study were lung, esophagus, prostate, breast, pancreatic, colorectal, stomach, brain and nervous system, ovarian and others ewing sarcoma, hepatocellular carcinoma, larynx carcinoma, bladder carcinoma, malignant mesenchymal tumor, multiple myeloma, primary unknown lymphoma, metastatic carcinoma of unknown primary, renal cell carcinoma, cervical carcinoma, testicular carcinoma cancers. The patients were at various stages of cancer, had various histological subtypes, and were receiving various chemotherapies. The  frequency of EBV, HSV, CMV and Parvovirus B19 in serum samples were determined. Results: The mean age of the patients was 58.93  13.28 years, and the mean duration of diagnosis was 2,0  2,2 years. EBV PCR positivity was detected in 9 patients 6.5, CMV PCR positivity in 12 patients 8.7, and EBV and CMV together PCR positivity in 1 0,7 patient. HSV and parvovirus B19 PCR positivitys were not determined in any patients. According to the results of the survival analysis, the average survival time in all lymphopenic patients was 3.71 months. It was observed that 65.21 of all lymphopenic patients die within 12 months following lymphopenia diagnosis. Conclusions: As a result of our study, EBV and CMV PCR positivity rates were determined in all lymphopenic patients receiving chemotherapy 6.5 and 8.7, respectively. More comprehensive studies are needed to determine the incidence of HSV and parvovirus B19. In addition, lymphopenic patients receiving chemotherapy should be followed up by physicians for viral infections and treated with antiviral therapy in the early stages of infection.

 GirişAmaç: Bu çalışmada kliniğimizde kemoterapi alan kanser tanısı almış hastalarda Epstein-Barr virüsü EBV, Herpes simpleks virüsü HSV, Sitomegalovirüs CMV ve Parvovirüs B19 viral enfeksiyonlarının sıklığını araştırmayı amaçladık. Yöntemler: Bu çalışmada Nisan 2018 - Temmuz 2018 tarihleri arasında Tıbbi Onkoloji Kliniğinde yatarak kemoterapi alan 138 lenfopenik hasta prospektif olarak değerlendirildi. Çalışmaya dahil edilen hastaların kanser tanıları akciğer, özofagus, prostat, meme, pankreas, kolorektal, mide, beyin ve sinir sistemi, over ve diğerleri Ewing sarkomu, hepatoselüler karsinom, larinks karsinomu, mesane karsinomu, malign mezenkimal tümör, multipl miyelom, primeri bilinmeyen lenfoma, primeri bilinmeyen metastatik karsinom, renal hücreli karsinom, servikal karsinom, testis karsinomu kanserleriydi. Hastalar çeşitli kanser evrelerindeydi, çeşitli histolojik alt tiplere sahipti ve çeşitli kemoterapiler almaktaydı. Serum örneklerinde EBV, HSV, CMV ve Parvovirus B19un  sıklığı belirlendi. Bulgular: Hastaların ortalama yaşı 58,93  13,28 yıl, ortalama tanı süresi 2,0  2,2 yıldı. EBV PCR pozitifliği 9 hastada 6,5, CMV PCR pozitifliği 12 hastada 8,7 ve EBV ve CMV birlikte PCR pozitifliği 1 hastada 0,7 saptandı. Hiçbir hastada HSV ve parvovirus B19 PCR pozitifliği saptanmadı. Sağkalım analizi sonuçlarına göre tüm lenfopenik hastalarda ortalama sağkalım süresi 3,71 ay olarak bulundu. Tüm lenfopenik hastaların 65,21inin lenfopeni tanısı konulduktan sonraki 12 ay içinde öldüğü görüldü. Sonuçlar: Çalışmamızın sonucunda kemoterapi alan tüm lenfopenik hastalarda EBV ve CMV PCR pozitifliği oranları belirlendi 6,5 ve 8,7. HSV ve parvovirüs B19 insidansını belirlemek için daha kapsamlı çalışmalara ihtiyaç vardır. Ayrıca kemoterapi alan lenfopenik hastalar viral enfeksiyonlar açısından hekimler tarafından takip edilmeli ve enfeksiyonun erken evrelerinde antiviral tedavi uygulanmalıdır.

Makale detayları

Investigation of Herpes Viridea and Parvovirus B19 Frequencies in Lymphopenic Malignant Patients Receiving Chemotherapy

Yazarlar:

Adil Furkan Kılıç | Salim Başol Tekin

Yayıncı:

Van Yuzuncu Yıl University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Van Sağlık Bilimleri Dergisi Vol.17 Issue 3, pp.159-165

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001337201

pISSN:

2667-5072

CMV

EBV

HSV

Lymphopenia

Parvovirus B19CMV

EBV

HSV

Lymphopenia

Parvovirus B19

Sayı

Makale detayları

Yazarlar: Adil Furkan Kılıç | Salim Başol Tekin

Yayıncı: Van Yuzuncu Yıl University

Ana Başlıklar: İç Hastalıkları

Dergi: Van Sağlık Bilimleri Dergisi Vol.17 Issue 3, pp.159-165

Belge Tipi: Makale

Yayın Tarihi: 12/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001337201

pISSN: 2667-5072

Sayı

Yazarlar:

Adil Furkan Kılıç | Salim Başol Tekin

Yayıncı:

Van Yuzuncu Yıl University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Van Sağlık Bilimleri Dergisi Vol.17 Issue 3, pp.159-165

Belge Tipi:

Makale

Yayın Tarihi:

12/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001337201

pISSN:

2667-5072